2021 AUA Annual Meeting Preview: Prostate, Bladder, and Kidney Cancer

The study achieved 100% local control and cancer-specific mortality rates with stereotactic ablative body radiotherapy.

In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.

In the first article of this series, Benjamin H. Lowentritt, MD, FACS, gives an overview of micronized abiraterone and its role in the treatment of patients with metastatic castrate-resistant prostate cancer.

Amar Kishan, MD, highlights findings showing that MRI-guided SBRT is superior to CT-guided SBRT in localized prostate cancer.

"It is erdafitinib’s time to shine," says Arlene O. Siefker-Radtke, MD.